The recently issued patent is assigned to the Mount Sinai School of Medicine (MSSM) and licensed exclusively to Vivaldi. The patent is part of an intellectual property portfolio from MSSM that includes more than 25 issued patents and numerous patent applications, to which Vivaldi has exclusive rights in the US and major international markets. The licensed MSSM patents cover four major patent families including compositions and methods of production for NS1-modified influenza vaccines, cell-substrate production methods, and assays for discovery of small-molecule inhibitors of NS1 with potential as antiviral drugs.

We are confident that Vivaldi ™s extensive patent estate, combined with its exclusive rights to the use of reverse genetics and plasmid rescue technologies for vaccines with modifications of NS1, will provide our products with long-term market exclusivity, said Douglass B. Given, MD, PhD, President and CEO of Vivaldi. This patent is an important component of Vivaldi ™s formidable intellectual property portfolio covering specific vaccine candidates and manufacturing techniques licensed from Mount Sinai School of Medicine in New York.

vivaldibiosciences/